Search

You searched for "therapy"

328 results found

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

12 October 2022 | | Urologic Oncology | #BladderCancer, #blcsm, cytosine arabinoside, intravesical therapy, mitomycin C, non-muscle-invasive bladder cancer, randomised trial, #uroonc, urinary pH
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...
Management of Prostate Cancer: A Multidisciplinary Approach book cover image

Management of Prostate Cancer: A Multidisciplinary Approach

4 September 2020 | | Urologic Oncology
This is an excellent textbook which comprehensively covers the vast field of prostate cancer. The editors, who have co-ordinated phase III European Organisation for Research and Treatment of Cancer (EORTC) trials, have brought together a large array of well-known international...

Sepsis syndrome in urology

1 November 2015 | | Infection
There are approximately 100,000 cases of sepsis per year in the UK, of which 37,000 result in death (this is more than prostate cancer, breast cancer, HIV / AIDS and road traffic accidents combined). Urosepsis is defined as sepsis caused...

Testosterone and erectile function – the debate goes on!

1 May 2018 | | Andrology, Basic Science Research
The most common causes of erectile dysfunction (ED) as per European Association of Urology (EAU) guidelines are: psychogenic, vasculogenic, neurogenic and hormonal. The EAU 2017 guidelines recommend measuring total testosterone (TS) level. This study is a meta-analysis of 14 randomised...
European Urology cover image

COVID-19: cancer and corticosteroids

4 September 2020 | | Urologic Oncology, COVID-19 - Urology News
Under the prevailing COVID-19 crisis, this article is well worth reading. The current World Health Organization (WHO) guidance is not to start steroids in cancer cases, but there is no clear evidence of risks with steroids in cancer patients having...
The Journal of Urology cover image.

Standard versus expanded cultures to diagnose UTIs in women

5 January 2022 | | Functional Urology, Infection | anti-bacterial agents, enhanced urine cultures, microbiota, urinary tract infections
Clinicians are well aware of the limitations of the so-called Kass criteria applied to standard urine culture (SUC) techniques as well as the limitations of empiric antibiotic prescribing for symptoms that are known to overlap with chronic conditions such as...

Cleveland Clinic / Imperial College – Antioxidant Online Survey

2 October 2020
Professor Ralf Henkel (Imperial College London/University of the Western Cape) and Professor Ashok Agarwal (Cleveland Clinic) are conducting an international online survey on the prescription of antioxidants for infertile patients, and have requested that we invite you to participate in this study.

Bladder cancer: where are we with intravesical therapies?

1 July 2016 | | Urologic Oncology
In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...

Intravesical GAG replacement therapies for bladder pain syndrome / interstitial cystitis – an update

4 May 2020 | | Functional Urology, Infection, Basic Science Research
The barrier function of the glycosaminoglycan (GAG) layer of the urothelium was identified by Parsons in 1975, and intravesical therapies to treat chronic inflammatory conditions of the bladder were developed soon after. However, the active role of the urothelium in...

Intravesical glycosaminoglycan analogue instillations for recurrent cystitis

1 May 2017 | | Infection, Functional Urology
Introduction The symptoms of recurrent cystitis can be triggered by inflammatory or infective causes. Bladder pain syndrome (BPS) and bacterial recurrent lower urinary tract infection can both present with symptoms of recurrent cystitis and cause significant morbidity in affected individuals....

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | Basic Science Research, Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Read all about it Mar/Apr 2019

1 March 2019 | Functional Urology, Urologic Oncology
Read all about it... It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a ‘cutting-edge’ new treatment / test and you don’t know what they are talking...